Regentis Biomaterials Ltd. (RGNT) — Working Capital to Net Assets Ratio
Regentis Biomaterials Ltd. (RGNT) has a Working Capital to Net Assets ratio of 100.0% as of December 2025. Working capital of $4.74 Million (current assets of $7.62 Million minus current liabilities of $2.87 Million) is measured against net assets of $4.74 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. For the complete balance sheet picture, see Regentis Biomaterials Ltd. total assets.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Regentis Biomaterials Ltd. Working Capital to Net Assets (2022–2025)
This chart shows how Regentis Biomaterials Ltd.'s Working Capital to Net Assets ratio has evolved across 4 annual periods from 2022 to 2025. As of December 2025, the ratio stands at 100.0%, reflecting working capital of $4.74 Million against net assets of $4.74 Million USD. Check Regentis Biomaterials Ltd. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Annual Working Capital to Net Assets for Regentis Biomaterials Ltd. (2022–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Regentis Biomaterials Ltd. from 2022 to 2025, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Read RGNT liabilities breakdown for a breakdown of total debt and financial obligations.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 100.0% | $4.74 Million | $4.74 Million | $7.62 Million | $2.87 Million | ▲ +85.4 pp |
| 2024 | 14.6% | $-6.01 Million | $-41.10 Million | $482.00K | $6.49 Million | ▲ +8.6 pp |
| 2023 | 6.1% | $-2.78 Million | $-45.91 Million | $360.00K | $3.14 Million | ▲ +3.9 pp |
| 2022 | 2.1% | $-892.00K | $-42.06 Million | $1.72 Million | $2.61 Million | — |